Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

“Our objective is to provide investors a list of stocks that may generate attractive returns on a long-term basis as the ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

As global markets rebound from recent sell-offs, with growth stocks notably outpacing value shares, the technology sector has shown remarkable resilience and potential. With economic indicators such ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Inc. (GILD) stock to Outperform rating, as announced on July 8, 2024, according to Finviz. Earlier, on May 1, 2024, Maxim Group had reiterated the stock to Buy, setting a price target of $85. for GILD ...

Climate change and conflict risk overshadowing efforts to improve people's health, when in reality the issues overlap, Peter ...

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

Yee notes that while Gilead's stock has not moved much over the last few years, it will likely take off as it moves forward with its new HIV prevention drug. "They have announced this week a second ...